Drug Trial Radar · NCT07156773
The Study is Being Conducted to Evaluate the Safety and Efficacy of XJN010 Nasal Spray in Patients With Parkinson's Disease Experiencing Off Episodes
Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Sep 3, 2025
Primary completion
Mar 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Guangzhou Novaken Pharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of XJN010 Nasal Spray in Patients with Parkinson's Disease Experiencing Off Episodes
Conditions
- Parkinson Disease
Interventions
XJN010 Nasal SprayDrug
In the XJN010 Nasal Spray group, subjects will receive XJN010 Nasal Spray,Based on the frequency of the "off" periods experienced by Parkinson's patients.
PlaceboDrug
In the XJN010 Nasal Spray blank preparation group, subjects will receive XJN010 Nasal Spray blank preparation, Based on the frequency of the "off" periods experienced by Parkinson's patients .
Primary outcomes
What the sponsor says the trial is designed to measure.
- MDS-UPDRS part III scoreTime frame: Day14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.